Table 3

The predicted cure rate and the actual cure rate for CDI patients in the validation database (all mITT patients in the 004 clinical trial with available values for all analyzed variables; n=452)
ATLAS score (nT) Predicted cure rate* (%) (nc§/nT) Actual cure rate (%) (nc/nT) Kappa P value
0 (69) 100 (69/69) 95.7 (66/69) N/A N/A
1 (89) 94.9 (84/89) 93.3 (83/89) 90.3% < 0.0001
2 (68) 89.8 (61/68) 92.7 (63/68) 81.8% < 0.0001
3 (86) 84.8 (73/86) 89.5 (77/86) 79.3% < 0.0001
4 (53) 79.7 (42/53) 81.1 (43/53) 94.1% < 0.0001
5 (46) 74.6 (34/46) 76.1 (35/46) 94.2% < 0.0001
6 (21) 69.5 (15/21) 85.7 (18/21) 58.8% 0.0031
7 (8) 64.4 (5/8) 50 (4/8) 75.0% 0.0285
8 (9) 59.4 (5/9) 55.6 (5/9) 100% 0.0027
9 (3) 54.3 (2/3) 33 (1/3) 40.0% 0.3865
10 (0) 49.2 (N/A) N/A N/A N/A
All scores (452) 86.3 (390/452) 87.4 (395/452) 95.2% < 0.0001

CDI patients categorized by the ATLAS scoring system, using the regression formula* derived from the ATLAS system applied to the 003 clinical trial. Testing the reliability of the predicted cure rate compared to the actual cure rate among individual ATLAS groups and for the entire population was done using Kappa statistics.

* Predicted cure rate = 100–5.08 x (ATLAS score).

nc : number of subjects cured in the category.

nT : total number of subjects in the category.

§nc values for the predicted column were rounded to the nearest whole number.

N/A: not applicable NS: not significant.

Miller et al.

Miller et al. BMC Infectious Diseases 2013 13:148   doi:10.1186/1471-2334-13-148

Open Data